Funding sources: This research was funded by the European Commission Seventh Framework Programme (FP7) and supported by researchers at the National Institute for Health Research University College London Hospitals Biomedical Research Centre.
Treatment of poor placentation and the prevention of associated adverse outcomes – what does the future hold?
Version of Record online: 29 MAY 2014
© 2014 The Authors. Prenatal Diagnosis Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Special Issue: Abnormal Placentation and Adverse Obstetric Outcomes: Screening, Diagnosis and Treatment
Volume 34, Issue 7, pages 677–684, July 2014
How to Cite
Spencer, R. N., Carr, D. J. and David, A. L. (2014), Treatment of poor placentation and the prevention of associated adverse outcomes – what does the future hold?. Prenat. Diagn., 34: 677–684. doi: 10.1002/pd.4401
Conflicts of interest: ALD is an unpaid consultant and director of Magnus Growth, part of Magnus Life Science, which is aiming to take to market a novel treatment for fetal growth restriction.
- Issue online: 8 JUL 2014
- Version of Record online: 29 MAY 2014
- Accepted manuscript online: 2 MAY 2014 06:03AM EST
- Manuscript Revised: 29 APR 2014
- Manuscript Accepted: 29 APR 2014
- Manuscript Received: 5 MAR 2014
- 8Bed rest in hospital for suspected impaired fetal growth. Cochrane Database Syst Rev 2000. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000034/full [accessed on 05 February 2014]., .
- 9Betamimetics for suspected impaired fetal growth. Cochrane Database Syst Rev 2001. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000036/full [accessed on 05 February 2014]., , .
- 10Calcium channel blockers for potential impaired fetal growth. Cochrane Database Syst Rev 2000. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000049/full [accessed on 05 February 2014]., .
- 11Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev 2003. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000137/full [accessed on 05 February 2014]., , .
- 12Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database Syst Rev 2003. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000148/full [accessed on 05 February 2014]., , .
- 13Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2008. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004227.pub3/full [accessed on 05 February 2014]., , , .
- 34Maternal delivery of Ad.VEGF gene therapy increases fetal growth velocity in an ovine paradigm of fetal growth restriction. Reprod Sci 2011;18(3 suppl):269A., , , et al.
- 35Local administration of Ad.VEGF-A165 to the uteroplacental circulation enhances fetal growth and reduces brain sparing in an FGR model of guinea pig pregnancy. Reprod Sci 2012;19(3):78A., , , et al.
- 36Royal College of Obstetrics and Gynaecology, Royal College of Radiologists, British Society of Interventional Radiology. Good Practice No. 6: The Role of Emergency and Elective Interventional Radiology in Postpartum Haemorrhage. London: RCOG, 2007.
- 50Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 7: Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality. London: RCOG, 2010.
- 51Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009. URL http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004661.pub3/full [accessed on February 2014]., , , et al.
- 52Australian Research Centre for Health of Women and Babies. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child. Adelaide: ARCH, 2010.
- 53American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 2010;115(3):669–71.
- 55National Collaborating Centre for Women's and Children's Health. NICE Clinical Guideline 127. Hypertension in Pregnancy: the Management of Hypertensive Disorders During Pregnancy. London: RCOG, 2010.
- 56American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine. Committee Opinion No. 573: Magnesium sulfate use in obstetrics. Obstet Gynecol 2013;122(3):727–8.
- 57Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 31: The Investigation and Management of the Small-for-Gestation-Age Fetus. London: RCOG, 2014.
- 58Effects of maternal tobacco-smoke exposure on fetal growth and neonatal size. Expert Rev Obstet Gynecol 2008;3(6):719–30., .
- 59Smoking cessation in the first trimester reduces most obstetric risks, but not the risks of major congenital anomalies and admission to neonatal care: a population-based cohort study of 1,164,953 singleton pregnancies in Finland. J Epidemiol Community Health 2014;68(2):159–64., , , et al.
- 76Pregnancy and Clinical Research. Hastings Cent Rep 2008;38(6):53., , .